Navigation Links
USC and second sight announce European clinical trial for Argus II retinal implant
Date:2/15/2008

Boston, MA, February 15, 2008 USC and Second Sight Medical Products Inc, leading developers of retinal prostheses for treating blindness, announced today that they have completed enrollment of the first phase of a U.S .FDA approved clinical study of the Argus II Retinal Prosthesis System. They also announced that enrollment at key European sites is underway as studies continue in Mexico.

We are pleased that Second Sight, along with our fantastic clinical partners, was able to fully enroll the US trial in a timely manner, said Robert Greenberg, MD, PhD, President and CEO of Second Sight, and a leader in the field of retinal prostheses for more than 15 years.

Although it is too early to comment on the clinical data, each device continues to function as expected, and all participants are using their systems at home daily.

The Argus II is the second generation of an electronic retinal implant designed for the treatment of blindness due to Retinitis Pigmentosa (RP), a group of inherited eye diseases that affect the retina. The Argus II implant consists of an array of 60 electrodes that are attached to the retina. These electrodes conduct information acquired from an external camera to the retina to provide a rudimentary form of sight to implanted subjects.

The development of this technology was largely supported by the National Eye Institute (NEI) of the National Institutes of Health (NIH), and the Department of Energys Office of Science (DOE) Artificial Retina Project, which is helping to advance the implants design and construction. The unique resources and expertise at DOE national laboratoriesparticularly in engineering, microfabrication, material science, and microelectronic technologiesare enabling the development of much smaller, higher resolution devices.

Ten subjects were recruited for the Phase I trial at four leading ophthalmic centers throughout the US, including the Doheny Eye Institute at the Univer
'/>"/>

Contact: Jon Weiner
jon.weiner@usc.edu
323-442-2830
University of Southern California
Source:Eurekalert

1

GOOD

Page: 1 2 3

Related biology technology :

1. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
2. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
3. Escalon(R) Reports Second Quarter Fiscal 2008 Results
4. Tianyin Pharmaceutical Co., Inc. Announces Second Quarter 2008 Financial Results
5. Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST
6. Update: Neurobiological Technologies Sets Date for Second Quarter Financial Results and Conference Call
7. ThermoGenesis Corp. Reports 48 Percent Growth in Second Quarter Revenues Year Over Year
8. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Second Quarter Results of Fiscal Year 2008
9. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
10. Nutrition 21 to Report Second Quarter Fiscal 2008 Financial Results Monday, February 11, 2008
11. Neurobiological Technologies Sets Date for Second Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)..., PLYMOUTH, Mass., Nov. 9 Har...announced today that the company sponsored 48-pati... the U.S. and one site in India using the company,... to treat patients with non-reconstructable Critic...Mark D. Iafrati, M.D. Chief of Vascular Surgery at...
(Date:11/9/2009)..., WASHINGTON, Nov. 9 /PRNewswire-USNewswire/ ...e American Humanist Association, held a panel disc... controversial emerging technologies in biomedical...ed by Jonathan Moreno and Andrew Light, both of th... issues from ethical and political angles. ,, ...
(Date:11/9/2009)..., BEIJING, Nov. 9 /PRNewswire-Asia-FirstC...), ("Yongye or "the Company") a leading manufactur... plant and animal nutrient products in the,People,... will conduct a,conference call at 10:00 a.m. East...mber 16, 2009 to discuss results for the quarter e...
(Date:11/9/2009)..., SCHIEDLBERG, Austria, November 9 /PRNew...ver the world have been working on the development...rect communication channel,between the brain and a...zed,patients to communicate or to control devices ...ng the last years some patients have been supervis...
Breaking Biology Technology:Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial 2Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club 2Jonathan Moreno and Andrew Light Speak About Biotechnology and Global Warming at the National Press Club 3Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 2Yongye International Announces Conference Call to Discuss Third Quarter 2009 Results 3intendiX - Communication by Thoughts: First Patient-Ready System on the Market 2
...are flexibility , Detect Released Oligosacchari... System , Angela R. Downs Deborah A. Greer Sta...iversity, Dover, DE , We compared the Eagle Eye ... SE2000 gel imager system,for imaging Fluorophor...s. The,data generated from either system were no...
...h integrated DNA-removal step , Karen Dolter...otal RNA miniprep kit efficiently,isolates high-...,cells or 10 to 40 mg of tissue and includes an on... samples can be processed simultaneously because o...n is performed within microspin cups,which elim...
...kits target specific mutations using molecular bea...Lingyu Chen Haoqiang,Huang Jason Zhang ,Stra...ation, molecular beacons ,can distinguish human... only a,single nucleotide. We developed three si...technology, to quickly detect three common human g...
Other Biology Technology:Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 2Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 3Detect Released Oligosaccharides Using the Eagle Eye II,Still Video Imaging System 4Simple Isolation of RNA from Tissue and Cultured Cells 2Simple Isolation of RNA from Tissue and Cultured Cells 3Simple Isolation of RNA from Tissue and Cultured Cells 4Simple Isolation of RNA from Tissue and Cultured Cells 5Simple Isolation of RNA from Tissue and Cultured Cells 6Simple Isolation of RNA from Tissue and Cultured Cells 7Simple Isolation of RNA from Tissue and Cultured Cells 8Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations 2Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations 3Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations 4Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations 5Fluorescence-Based Single-Tube Assays to Rapidly Detect Human Gene Mutations 6
(Date:11/9/2009)...e for the rapid, mysterious death of phytoplankton...laborating scientists at Rutgers University and th...is same chemical may hold unexpected promise in ca...y unknown lipid, or fatty compound, in a virus tha...i , a phytoplankton that plays a major role in the...
(Date:11/9/2009)... A nutritionist whose research was instrumental i...n, Infants and Children (WIC) food subsidy will re...utstanding achievement in the field of maternal-fe...a professor in the Department of Community Health ...les School of Public Health, will receive the awar...
(Date:11/8/2009)...e loss of a gene through deletion of genetic mater...t abnormalities in learning and behavior, said a c...Medicine ( www.bcm.edu ) in a report that appears ... "This research goes about 95 percent of the way t...dividuals to this gene," said Dr. Arthur L. Beaude...
Breaking Biology News(10 mins):Newly discovered fat molecule: An undersea killer with an upside 2Newly discovered fat molecule: An undersea killer with an upside 3Newly discovered fat molecule: An undersea killer with an upside 4March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2Developmental delay could stem from nicotinic receptor deletion 2Highmark Caring Place To Honor Midstate Volunteers 48566 1Highmark Caring Place To Honor Midstate Volunteers 48566 2Highmark Caring Place To Honor Midstate Volunteers 48566 3New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 1New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 2New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 3New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 4New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 5New Phase 3 Data Continue to Indicate that Wyeths Investigational 13 valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease 12578 6PAREXEL Enhances Study Start Up and Recruitment Capabilities With Appointment of Dr Lars Olof Eriksson Formerly With Merck 48561 1PAREXEL Enhances Study Start Up and Recruitment Capabilities With Appointment of Dr Lars Olof Eriksson Formerly With Merck 48561 2PAREXEL Enhances Study Start Up and Recruitment Capabilities With Appointment of Dr Lars Olof Eriksson Formerly With Merck 48561 3PAREXEL Enhances Study Start Up and Recruitment Capabilities With Appointment of Dr Lars Olof Eriksson Formerly With Merck 48561 4PAREXEL Enhances Study Start Up and Recruitment Capabilities With Appointment of Dr Lars Olof Eriksson Formerly With Merck 48561 5
...ute of Virology and Immunology (GIVI) have identif...), a protein that acts against HIV, a finding that...fection. , The work is published today, Oct. 2, ...iences, USA. , The research, conducted by scient...Greene, MD, PhD, explains why CD4 T cells ?the imm...
...roke, paramedics, doctors, and nurses follow stand...heir efforts improve your odds for a full recovery...ction known as sepsis, which can be fatal within a...too late. , Now, a new, multicenter research cons...Shock (ProCESS), is beginning a large-scale study ...
...stem controls HIV during the earliest phases of in...sions of key immune-system molecules called HLA Cl...fragments of viral protein those molecules display...d cells. In a report in the November issue of PLO...earch Center at Massachusetts General Hospital (PA...
Other Biology News:Gladstone investigators identify a new protective action for the powerful anti-HIV factor, APOBEC3G 2New study aims to stop sepsis in its tracks 2New study aims to stop sepsis in its tracks 3Early-stage immune system control of HIV may depend on inherited factors 2Early-stage immune system control of HIV may depend on inherited factors 3
HeLa Cell Slide from ProSci, Inc
EL4 Cell Slide from ProSci, Inc
IHC Select TE Buffer pH 9.0 [Antigen/ Epitope Retrieval Reagent], 10x from CHEMICON
Hep G2 Cell Slide from ProSci, Inc
Biology Products: